UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 18, 2015
|
ADMA BIOLOGICS, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
||
|
Delaware
|
001-36728
|
56-2590442
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
465 State Route 17 Ramsey, New Jersey
|
07446
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (201) 478-5552
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 - Entry into a Material Definitive Agreement.
On December 18, 2015, ADMA Biologics, Inc. (the "Company") entered into Amendment No. 2 ("Amendment No. 2") to the Plasma Purchase Agreement (the "Purchase Agreement"), dated November 17, 2011, between the Company and Biotest Pharmaceuticals Corporation ("Biotest"), as amended on December 1, 2011, for the purchase of normal source plasma containing antibodies to Respiratory Syncytial Virus ("RSV") to be used in the manufacture of RI-002. Amendment No. 2, among other things, expands the circumstances under which the Company may purchase additional plasma from sources other than Biotest.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
December 23, 2015
|
ADMA Biologics, Inc.
|
||
|
By:
|
/s/ Brian Lenz
|
||
|
Name:
|
Brian Lenz
|
||
|
Title:
|
Chief Financial Officer
|
||